Login to Your Account

GSK Pays $212M for Preclinical Work

Immunocore Fills Out Dance Card with Another Mega Deal

By Nuala Moran
Staff Writer

Tuesday, July 9, 2013
LONDON – Immunocore Ltd. has done it again, landing a multi-target pact with Glaxosmithkline plc (GSK), featuring a combined price tag of £142 million (US$212 million) for preclinical development followed by up to £200 million (US$299 million) per program in clinical and commercialization milestones, and double-digit royalties on sales.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription